Floatz Rating
BB68/100
Confidence
Indicative
Sponsor
Endeavor Health
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
57High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05241873CT.gov (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations | — | Terminated | — | — | — |
NCT05153408CT.gov (HARMONY) Study of BLU-701 in EGFR-mutant NSCLC | — | Terminated | — | — | — |
NCT05749016CT.gov Neoadjuvant Inetetamab Combined With Pertuzumab and Paclitaxel/Carboplatin for Breast Cancer | — | Unknown | — | — | — |
NCT04807166CT.gov Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer | — | Active Not Recruiting | — | — | — |
NCT04860674CT.gov A Prospective Study of PD-1 Inhibitor Combined With ICE in the Treatment of Relapsed/Refractory Gray Area Lymphoma | — | Unknown | — | — | — |
NCT03777124CT.gov Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer | — | Terminated | — | — | — |
NCT01562301CT.gov Sublingual Anvirzel in Advance Non-Small Cell Lung Cancer (NSCLC) | — | Withdrawn | — | — | — |
NCT02311907CT.gov Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Chemotherapy-Induced Toxicity
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Carboplatin (this asset) | Endeavor Health | P3 | BB · 68 |
| Palonosetron | Second Affiliated Hospital, School of Medicine, Zhejiang University | P4 | A |
| Dexasone | Instituto do Cancer do Estado de São Paulo | P4 | A |
| Phosphonic Acid, P-[3-[[(2R,3R)-2-[(1R)-1-[3,5-Bis(Trifluoromethyl)Phenyl]Ethoxy]-3-(4-Fluorophenyl)-4-Morpholinyl]Methyl]-2,5-Dihydro-5-Oxo-1H-1,2,4-Triazol-1-Yl]- | Second Affiliated Hospital, School of Medicine, Zhejiang University | P4 | BBB |
| HR20013 | Fujian Shengdi Pharmaceutical Co., Ltd. | P3 | BB |
| Netupitant | Instituto Brasileiro de Controle do Cancer | P3 | BB |
| Docetaxel | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | P4 | BB |
| Ondansetron | Dr Atul Sharma | P3 | BB |
| Nivestim | Centre Francois Baclesse | P3 | BB |
+42 more in the Chemotherapy-Induced Toxicity cohort
Other indications for Carboplatin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Lung Large Cell Carcinoma | — | P4 | A · 80 |
| Primary Peritoneal Carcinoma | — | P3 | BBB · 76 |
| Non-Small Cell Squamous Lung Carcinoma | — | P3 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- PalonosetronSecond Affiliated Hospital, School of Medicine, Zhejiang UniversityA
- DexasoneInstituto do Cancer do Estado de São PauloA
- Phosphonic Acid, P-[3-[[(2R,3R)-2-[(1R)-1-[3,5-Bis(Trifluoromethyl)Phenyl]Ethoxy]-3-(4-Fluorophenyl)-4-Morpholinyl]Methyl]-2,5-Dihydro-5-Oxo-1H-1,2,4-Triazol-1-Yl]-Second Affiliated Hospital, School of Medicine, Zhejiang UniversityBBB
- HR20013Fujian Shengdi Pharmaceutical Co., Ltd.BB
- NetupitantInstituto Brasileiro de Controle do CancerBB
Citation
Floatz Terminal. Carboplatin in Chemotherapy-Induced Toxicity. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/carboplatin-chemotherapy-induced-toxicity-41553
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →